Pharmaceutical Technology
APRIL 20, 2023
In the first phase of its training workshops, the Pharmaceutical Innovation Center plans to develop a range of excipients [inactive substances that serve as the vehicle or medium for a drug or other active substance] for controlled release dosage forms, improving their bioavailability, along with formulating orally dispersible and chewable tablets.
Camargo
FEBRUARY 10, 2021
A failure to demonstrate BE may suggest that the test product should be reformulated, that the manufacturing method should be changed, that additional safety or efficacy data may be needed, or that the study was not properly powered for sample size. Pharmacokinetics Scientist. Co-Authors: Galina Bernstein, PhD. Uma Fogueri, PhD.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cloudbyz
MARCH 5, 2024
Manufacturing Process : Small Molecules: Manufactured through chemical synthesis, small molecule drugs can be consistently reproduced with a high degree of purity and stability. The conditions affecting the living system can influence the final product, making the manufacturing process more sensitive and challenging.
Pharmaceutical Technology
JANUARY 25, 2023
According to a whitepaper from contract research, development and manufacturing organisation Syngene, PROTACs are effective against “undruggable” targets such as transcription factors, and scaffolding proteins that cannot be otherwise targeted by the traditional small molecule inhibitors.
Camargo
DECEMBER 22, 2021
In addition to prioritizing programs most closely aligned with sponsor objectives, a portfolio analysis can help prevent a program from failing due to misalignment of the various factors that affect drug development, including clinical, nonclinical, regulatory, scientific, manufacturing, and market dynamics. Scientist, Regulatory Strategy.
Drug Discovery World
AUGUST 3, 2022
CDMO in peptides and oligonucleotides manufacturing, Bachem, has started building a new future for oligonucleotides: solving the industry’s main challenges around capacity, sustainability and cost-effectiveness. Ensuring that the CPP can escape this endosomal compartment is crucial for its bioavailability and bioactivity properties.
Roots Analysis
MAY 21, 2024
In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.
Expert insights. Personalized for you.
130 
Let's personalize your content